Phillip Parente

Adj ClinAssProf

If you made any changes in Pure these will be visible here soon.

Personal profile


Dr Philllip Parente trained at Monash University graduating with First Class Honours in 1993. He completed training in Medical Oncology 2001 and completed a 2 year Fellowship in Immunology and Melanoma at Ludwig Institute For Cancer Research at Austin Health. Initially he worked as a Medical Oncologist at both Eastern Health and Austin Health however since becoming Deputy Director of Medical Oncology Box Hill Hospital in 2005 has solely worked at Eastern Health. Currently Dr Parente is the Acting Director of Cancer Services Eastern Health.

His main areas of interest are Genitourinary Cancers, Lung Cancers and Melanoma and he is considered a clinical lead in these areas of oncology. With respect to oncology research he is principal investigator of numerous trials in his areas of interest. This has translated to numerous publications and presentations at local and international oncological conferences. He often gives presentations on his areas of interests to trainees and peers.

Dr Parente has a particular interest in teaching and training. He has been a Senior Lecturer, Faculty of Medicine, Monash University since 2002. He has coordinated Year 3 medical student teaching at Eastern Health for last 10 years. He is on the National Examining Panel for the Royal Australasian College of Physicians and was the chairperson of the Victorian Medical Oncology Trainee Program between 2006 - 2010 transforming the program into a centralised computer matching process which resulted in the program being the most competitive for oncology training in Australia.

Clinical activities

Acting Director of Medical Oncology - Box Hill

Medical Oncologist

Specialist Advisory Committee Member - Medical Oncology - Royal College of Physicians, Lead in Assessment

Research interests

Melanoma, Lung Cancer, Urological Cancers.

Supervision interests

Director of Undergraduate 3rd Year Teaching - Box Hill Hospital

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2003 2019

2 Citations (Scopus)

Exploring the spectrum of late effects following radical orchidectomy for stage I testicular seminoma: a systematic review of the literature

Soon, J. A., Anton, A., Torres, J., Lawrence, R., Parente, P., McKendrick, J., Davis, I. D. & Pezaro, C., 1 Feb 2019, In : Supportive Care in Cancer. 27, 2, p. 373-382 10 p.

Research output: Contribution to journalReview ArticleResearchpeer-review

Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer

Kwan, E. M., Fettke, H., Docanto, M. M., To, S. Q., Bukczynska, P., Mant, A., Pook, D., Ng, N., Graham, L. J. K., Mangiola, S., Segelov, E., Mahon, K., Davis, I. D., Parente, P., Pezaro, C., Todenhöfer, T., Horvath, L. G. & Azad, A. A., 15 May 2019, (Accepted/In press) In : European Urology Focus. 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC)

Kwan, E. M., To, S. Q. G., Fettke, H. C., Docanto, M., Bukczynska, P., Mant, A. M., Pook, D. W., Ng, N., Graham, L. J. K., Segelov, E., Mahon, K. L., Davis, I., Parente, P., Pezaro, C., Horvath, L. G. & Azad, A., 1 Mar 2019, In : Journal of Clinical Oncology. 37, 7 Suppl, p. 188 1 p.

Research output: Contribution to journalMeeting AbstractOtherpeer-review

44 Citations (Scopus)

Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Maio, M., Lewis, K., Demidov, L., Mandalà, M., Bondarenko, I., Ascierto, P., Herbert, C., Mackiewicz, A., Rutkowski, P., Guminski, A., Goodman, G. R., Simmons, B., Ye, C., Yan, Y. & BRIM8 Investigators, 1 Apr 2018, In : Lancet Oncology. 19, 4, p. 510-520 11 p.

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)

Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis–targeting Agents in Metastatic Castration-resistant Prostate Cancer

To, S. Q., Kwan, E. M., Fettke, H. C., Mant, A., Docanto, M. M., Martelotto, L., Bukczynska, P., Ng, N., Graham, L. J. K., Parente, P., Pezaro, C., Mahon, K., Horvath, L., Todenhöfer, T. & Azad, A. A., 1 Jun 2018, In : European Urology. 73, 6, p. 818-821 4 p.

Research output: Contribution to journalArticleResearchpeer-review